Navigation Links
UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting
Date:11/4/2011

ATLANTA, Nov. 4, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is marking the 2011 American College of Rheumatology (ACR) meeting by reinforcing its commitment to people living with rheumatoid arthritis (RA) and their healthcare providers. At this year's ACR meeting, UCB is proud to sponsor several key sets of data with new findings on patient-reported quality of life measures, including work and household productivity, as well as other clinical response measures.

"The annual ACR meeting is an excellent opportunity to demonstrate UCB's commitment to rheumatologists and their patients," said Neil McFarlane, Vice President, Immunology Business Unit, UCB, Inc.  "Through our body of data at this year's meeting, it is our goal to engage in meaningful dialogue regarding optimal treatment for rheumatoid arthritis."

UCB will not have a promotional booth at the meeting this year, but will staff a medical booth to respond to questions from health care providers.

An Enduring Passion for Patient Care

UCB continues to demonstrate its aspiration of being the patient-centric global biopharmaceutical leader that transforms the lives of people living with severe diseases through scientific research, advocacy and programming.  The company provides financial support for important professional and patient programs, including:

Within Our Reach: Finding a Cure for Rheumatoid Arthritis Campaign: UCB is a Pinnacle donor of the $30-plus million ACR Research and Education Foundation (REF) campaign to fund a multi-year research initiative to accelerate high-risk, high-reward research in rheumatoid arthritis not normally funded by the National Institutes of Health or other peer reviewed funding sources. Investigator-initiated and pilot grants are awarded to projects that address basic, translational, and clinical aspects of rheumatoid arthritis.

ACR REF Industry Roundtable: The roundtable brings together leaders from the ACR REF and the pharmaceutical industry in a dynamic partnership, with the goal of ensuring that well-trained, qualified rheumatologists are entering the field and making advancements in patient care.

Harvard-UCB Research Alliance: The alliance was forged to build a unique drug discovery bridge between industry and academia by pushing the boundaries of translational research in order to change the lives of patients. UCB has committed $6 million over the next 2 years to fund innovative research led by Harvard scientists.

UCB RA Scholarship Program: Since 2008, UCB has awarded 101 scholarships, totaling $1,000,000 in education support. Scholarships are awarded to students diagnosed with rheumatoid arthritis and immediate family members of rheumatoid arthritis patients who are seeking higher education. The scholarship selection committee is comprised of top-ranking rheumatologists, a rheumatology nurse practitioner, and a patient with rheumatoid arthritis.

Reach Beyond RA: A vibrant and newly redesigned online patient resource, www.ReachBeyondRA.com offers robust lifestyle content for patients interested in solutions to better manage their lives with rheumatoid arthritis. The site includes:

  • Access to MyRAFitKit, a customizable fitness program designed specifically for patients with rheumatoid arthritis
  • Managing RA: The Strong Woman's Approach, a new initiative created by UCB and HealthyWomen to help educate, inspire, and empower women living with rheumatoid arthritis
  • Access to HelpPayRA, a library of financial assistance resources to help patients cover the costs of rheumatoid arthritis treatment

Arthritis Foundation Corporate Sponsorship: UCB's ongoing sponsorship of the Arthritis Foundation helps to raise awareness about arthritis, strengthen research efforts, and provide education to patients living with arthritis.

RA Local Events Sponsorships: UCB supports a number of local events for people living with rheumatoid arthritis to help educate individuals on managing their arthritis and to provide information on resources and tools to assist patients with improving.

For further Information:
Andrea Levin, Senior Manager, Communications and PR, UCB, Inc.
404.483.7329, Andrea.Levin@ucb.com

Dena Koklanaris, Cooney/Waters Group
212.886.2228, dkoklanaris@cooneywaters.com

About Rheumatoid Arthritis (RA)

RA affects more than 1.3 million Americans, and it is estimated that 5 million people suffer from RA globally. Prevalence is not split evenly between genders, since women are three times more likely to be affected than men. Although RA can affect people of all ages, the onset of the disease usually occurs between 35-55 years of age.

About UCB

UCB, Brussels, Belgium (www.ucb-usa.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in more than 40 countries, the company generated revenue of euro 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For further information on UCB products, please visit www.UCB.com.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management.  Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Brain Fitness Survey Reinforces Importance of Brain Awareness Week
2. Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol
3. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
4. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
5. Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R)
6. Scientists take up golf to prove long-standing theory of cell stickiness
7. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
8. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy
9. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
10. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
11. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):